Running title: Genomic analysis of Temozolomide resistance in DLBCL. The mechanisms contributing to TMZ resistance are unknown.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Despite recent advances in the treatment for diffuse large B-cell lymphoma, there remains a largely unmet need for better treatments in relapsed and refractory disease. The alkylating agent Temozolomide (TMZ) has activity in primary central nervous system lymphoma, but its role in treatment of systemic DLBCL is yet to be explored. Using integrative gene expression and methylation analysis, we herein identify a gene expression signature associated with TMZ resistance and identify Decitabine using connectivity mapping to reverse this resistance to TMZ (3-5), cutaneous T cell lymphoma (6), and acute myeloid leukemia (5). It is an attractive chemotherapeutic drug because it reveals good bioavailability after oral administration, good tissue penetration, and has minimal side effects. Since DLBCLs are responsive to alkylating agents and DLBCL-PCNSLs respond to TMZ, this drug may be useful in systemic DLBCLs as well. The activity of DNA repair enzyme Methyl-guanine DNA methyltransferase (MGMT) is known to be a major mechanism of resistance to this drug in human cancers, with loss of MGMT function more frequently due to promoter region methylation than to gene deletion or mutation (7). Epigenetic silencing of MGMT expression by promoter methylation of MGMT is associated with improved clinical outcomes in glioblastoma (1) and it also appears to be a useful marker for predicting survival in patients with DLBCL treated with alkylating agent-based chemotherapy (8).
In the current study, we use a systems biology approach combining integrative gene expression analysis, genomic methylation analysis and connectivity mapping to identify the genomic and epigenomic differences associated with resistance to TMZ in DLBCL, and validate 5-aza-2-deoxycytidine (Decitabine, DAC) as a potential compound to overcome TMZ resistance. standard curve. Cell viability in drug-treated cells was normalized to their respective untreated controls. Cell counts were confirmed on the Countess automated cell counter (Life Technologies, Carlsbad, CA) according to the manufacturer's specifications.
DNA methylation analysis by the HpaII tiny fragment Enrichment by Ligation-mediated PCR (HELP)
Genomic DNA was isolated from cell lines with the use of a standard high-salt procedure, and the HELP assay was carried out as previously described (9), (10). The assay uses comparative isoschizomer profiling, interrogating cytosine methylation status on a genomic scale. Briefly, genomic DNA from the samples was digested by a methylcytosine-sensitive enzyme HpaII in parallel with MspI, which is resistant to DNA methylation, and then the HpaII and MspI products were amplified by ligation-mediated PCR. PCR conditions have been optimized to amplify fragments between 200 and 2000 base pair (bp), thus ensuring the preferential amplification of cytosine-phosphate-guanosine (CpG) dinucleotide-dense regions. Each fraction is then labeled with a specific dye and cohybridized onto a microarray designed to cover HpaII amplifiable fragments (HAFs) across the genome (10). The differential digestion of DNA by the 2 restriction enzymes HpaII (methylation sensitive) and MspI (methylation insensitive) assays the methylation of genomic DNA covered in the microarray probes. Detailed descriptions of HELP methods and conditions have been previously published (9), (10). DNA methylation was measured as the log (HpaII/MspI) ratio, ranging from í3.17 to 6.05, where HpaII reflects the hypomethylated fraction of the genome and MspI represents the whole genome reference.
Fractions were labeled with the use of cyanine-labeled random primers (9-mers) and then hybridized onto a human HG17 custom-designed oligonucleotide array (50-mers) covering across the microarray slide. All samples for microarray hybridization were processed at the Roche-NimbleGen Service Laboratory. Scanning was performed with the use of a GenePix 4000B scanner (Axon Instruments). PCR fragment length bias was corrected by quantile normalization. Further quality control and data analysis of HELP microarrays were performed as described in Thompson et al. (11) . All microarray data have been submitted to the Gene Expression Omnibus repository. Figure 1B) . Briefly, PCR primers specific for bisulfite-converted genomic DNA were designed using Sequenom EpiDesigner to cover the flanking HpaII sites for a given HAF, as well as any other HpaII sites found up to 2,000 bp upstream of the downstream site and up to 2,000 bp downstream of the upstream site (Primer sequences indicated in Supplementary Table S1 ).
Microarray data analysis, gene network and gene ontology analysis
Gene expression data were obtained using the Affymetrix HuGene ST 1.0 GeneChip; mRNA isolation, labeling, hybridization, and quality control were carried out as described previously (10). Raw data were processed using the Robust Multi-Averaging (RMA) algorithm ͺ resistance was assessed using a conventional T-test with a p-value < 0.01 and differences of mean of genes differentially expressed between resistant and sensitive cell lines >1.0. This cutoff was chosen in order to provide a reasonably-sized set of probes and to increase the likelihood of detecting biologically significant changes in expression levels. The Database for Annotation, Visualization and Integrated Discovery (13) and Ingenuity Pathway Analysis software were used to carry out network composition analyses (http://www.ingenuity.com/products/pathways_analysis.html).
The GEP data was then analyzed with the Broad Institute's CMAP database (http://www.broadinstitute.org/cmap/index.jsp), using the same set of differentially expressed genes in resistant vs. sensitive cell lines. With CMAP, our imported query was compared with established signatures of therapeutic compounds (or "perturbagens"). Each compound was assigned a connectivity score (from +1 to -1), representing relative association with our specific query. Compounds with connectivity scores closest to -1 were considered most likely capable of reversing the gene pattern of our query (i.e., overcoming resistance), and were therefore considered the best candidates for functional validation in an attempt to confer TMZ sensitivity.
Quantitative Real time Polymerase Chain Reaction (RT-PCR)
RNA was extracted from cells using TRIzol (Invitrogen, Carlsbad, CA) as in the manufacturer's protocol. cDNA was prepared using Superscript III First Strand cDNA Synthesis kit (Invitrogen, Carlsbad, CA) and detected by SybrGreen (Applied Biosystems, Foster City, CA) on an Opticon2 thermal cycler (MJ Research, Waltham, MA). Gene expression was normalized to hypoxanthine phosphoribosyltransferase (HPRT) and expressed relative to untreated control using the ǻǻCT method. Thermal cycler conditions were: initial step of 10 min at 95°C followed by 40 cycles of 15 sec at 95°C (denature) and 1 min at 60°C (anneal/extend). For primers, see Supplementary Table S2 . alone group, which received a dose of 50mg/kg by oral gavage for a total dose 250mg/kg during 5 days on day 1, 2, 3, 4, and 5 as previously published for PCNSL models (14); (2) DAC alone group, which received 3 injections of 0.2mg/kg given by i.p. every other day for 2 weeks (day 1, 3, 5, 8, 10, and 12) -1.2mg/kg total dose; (4) combination group, which received both TMZ and DAC at doses described above; (1) control group, which received saline by oral gavage during 5 days on day 1, 2, 3, 4, and 5. Tumors volume and weight were assessed every three days. The
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RESULTS
Temozolomide has activity in a subset of DLBCL cell lines independent of MGMT expression or promoter methylation
A panel of 15 DLBCL cell lines was exposed to different doses of TMZ (25-2500μM) in both single and multi-day schedules (50μM of TMZ every 24 hours for 5 days). We divided our panel into two groups "sensitive" and "resistant" using a single dose IC50 cutoff of 150μM, which represents the clinically achievable concentration of drug (2) ( Figure 1A ). To determine whether MGMT expression or promoter methylation could predict resistance or sensitivity amongst the DLBCL cells, we first compared MGMT protein and mRNA levels to TMZ response in these cell lines ( Figure 1A, Supplementary Figure S1A ). All TMZ-sensitive cell lines expressed some MGMT protein/mRNA, however lack of MGMT did not confer sensitivity to TMZ, as 50% of TMZresistant cell lines were MGMT negative. Figure 2C ). Decitabine, a pyrimidine nucleoside analog of cytidine, was approved by the FDA as an orphan drug for treatment of myelodysplastic syndromes (16). DAC is of particular interest because epigenetic reprogramming in cancer using DAC has been shown to overcome chemotherapy resistance (17). Moreover, the specific combination of DAC and extended-schedule TMZ was capable of reversing clinical TMZ resistance in melanoma (18).
Research. Figure 3A) . We further compared differentially methylated and expressed probes in TMZ resistant DLBCL cell lines and found 152 Refseq probes corresponding to 160 genes that were both differentially methylated and expressed ( Figure 3B, Supplementary Table S5 ). Nineteen out of 160 differentially methylated and expressed genes, i.e. C7orf54, CCNJ, CDKN2AIP, CENPJ, HNRNPD, IGLL1, LOC100287552, MAPKAPK5, METTL13, PLK4, S1PR4, SMAD1, SPTBN1, STAG2, TMSB15B, TOP2B, ZNF551, ZNF567, and ZNF74 , are found to be hyper methylated and under expressed in TMZ-resistant DLBCL cell lines as shown on Figure 3C . HNRNPD, SMAD1, ZNF551, ZNF567, and ZNF74 are involved in regulation of transcription; MAPKAPK5 and PLK4 are protein kinases, IGLL1 is known to be one of B-cell differentiation markers and TOP2B controls DNA replication. We are particularly interested in these genes, because their expression can be potentially induced using demethylating agent DAC (detected by CMAP as a candidate compound). TGFB/BMP signaling is known to affect proliferation, survival and differentiation of lymphocytes. Repression of SMAD1 in particular has been associated with resistance to doxorubicin in DLBCL (19). In our experiments, DAC induced SMAD1 mRNA 3-9 fold, up to 3.5 fold, and 2-fold in SUDHL-6, Ly10, and Ly3 DLBCL cells, respectively (Supplementary Figure   S2B-D) . We confirmed our findings by Western blotting validation of SMAD1 and phospho-SMAD1 protein expression after DAC treatment ( Figure 3D, Supplementary Figure 2E) . TGFbeta induction of phospho-SMAD1 was used as a positive control in these experiments. 
ͳ͵
DAC is synergistically cytotoxic in combination with TMZ in vitro and in vivo causing complete responses in TMZ resistant DLBCL xenograft models
We next asked the question whether the combination of DAC and TMZ could overcome resistance to TMZ in DLBCL. We pre-treated TMZ resistant cell lines SUDHL-6, Ly10, and Ly3 cells with hypomethylating (i.e. non DNA damaging) doses of DAC for 72 hours and then with IC25-IC50 concentrations of TMZ for another 48 hours. We found that DAC synergizes with TMZ in reduction of cell viability ( Figure 4A-B, Supplementary Figure S3A ). The drug combination indices for DAC and TMZ were well below 1 cutoff for Ly3, Ly10, and SUDHL-6 cells representing the synergistic effect of the 2 drugs ( Figure 4A -B, Supplementary Figure   S3A ).
In vivo, we used three cell lines SUDHL-6, Ly10 and Ly3 for the xenograft experiments. Mice were divided into 4 treatment cohorts: vehicle control, TMZ alone, and DAC alone and the combination of DAC and TMZ were evaluated. TMZ as a single agent had a statistically significant tumor growth inhibition compared both with control and cohort treated with DAC single drug in SUDHL-6 murine xenograft model ( Figure 4C ). Four out of nine animals (44.4%) had complete response by day 21 of the beginning of treatment in TMZ alone group. However, the combination of TMZ and DAC caused complete response in nine out of nine mice (100%) by day 18 after treatment started. Statistically significant tumor growth inhibition was observed in DAC alone cohort of animals comparing to control group by day 24 (P <.03) ( Figure 4C ). There was no significant weight loss (i.e. > 10%) in all the treated mice. For Ly10 and Ly3 murine xenograft models, five out five (100%) mice had complete response by day 9 and day 12 of the beginning of treatment in drug combination group, respectively ( Figure 4D Based on recent investigation, SMAD1 hypermethylation in patients with lymphoma was associated with more chemoresistant subtypes of DLBCLs (ABC-DLBCLs) and poorer overall survival after standard therapy (19). Prolonged exposure to low-dose DNMT inhibitors (DNMTI) reprogrammed chemoresistant cells to become doxorubicin sensitive while reactivation of SMAD1 was required for chemosensitization (19) . The other 18 genes hyper-methylated in TMZ resistant DLBCL cell lines may also serve as potential biomarkers for response to TMZ.
In summary, our results demonstrate that the integration of genome-wide promoter methylation, gene expression, and drug discovery using connectivity mapping can be effective in identification of novel therapeutic targets and mechanisms of overcoming drug resistance. We also identify demethylating agent DAC treatment as capable of producing complete responses in vivo in in TMZ-resistant DLBCL and suggest epigenetic repression of TGFȕ/SMAD1 as a resistance mechanism, which can be potently overcome in vivo using DAC to improve the depth of response in patients with relapsed DLBCL or PCNSL. Table 2 . GSEA categorizes differentially expressed in TMZ resistant cell lines by gene families.
Gene Family
Number of genes
Cytokines and growth factors 12
Transcription factors 36
Homeodomain proteins 3
Cell differentiation markers 15
Protein kinases 20
Translocated cancer genes 11
Oncogenes 12
Tumor suppressors 3
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on Ly10 DLBCL xenograft models. Plots represent summary of two independent experiments for each cell line. N=7 in DAC alone and control groups; N=9 in TMZ alone and combination groups for SUDHL-6 xenograft experiments. N=5 in each group for Ly10 DLBCL xenograft model.
